GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (NAS:PGEN) » Definitions » Total Current Liabilities

Precigen (Precigen) Total Current Liabilities : $22.99 Mil (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Precigen Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Precigen's total current liabilities for the quarter that ended in Dec. 2023 was $22.99

Precigen Total Current Liabilities Historical Data

The historical data trend for Precigen's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precigen Total Current Liabilities Chart

Precigen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 122.91 42.13 34.65 78.65 22.99

Precigen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.65 46.73 30.77 32.88 22.99

Precigen Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Precigen's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=13.024+1.202
+Other Current Liabilities+Current Deferred Liabilities
=8.25+0.509
=22.99

Precigen's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=13.024+1.202
+Other Current Liabilities+Current Deferred Liabilities
=8.25+0.509
=22.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Precigen Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Precigen's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Precigen (Precigen) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (NAS:PGEN) » Definitions » Total Current Liabilities
Comparable Companies
FUSN QURE KALV AVTE RPHM MGTX JANX THRD VIGL AURA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
I5X:Germany I5X:Germany
Address
20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Website
http://www.precigen.com
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Executives
Jeffrey B Kindler director 35 E. 62ND ST, NEW YORK NY 10065
Randal J Kirk director, 10 percent owner, officer: Chief Executive Officer 1881 GROVE AVENUE, RADFORD VA 24141
Dean J Mitchell director C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Helen Sabzevari director, officer: President and CEO 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Rutul R Shah officer: Chief Operating Officer C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Harry Jr. Thomasian officer: Chief Financial Officer C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD 20876
Jeffrey Thomas Perez officer: SVP, IP Affairs 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Donald P. Lehr officer: Chief Legal Officer 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Steven Frank director 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Vinita D Gupta director 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Robert B Shapiro director 155 WEST BURTON PLACE, #2, CHICAGO IL 60610
Cesar L Alvarez director C/O PEDIATRIX MEDICAL GROUP, LEGAL DEPT 1301- CONCORD TERRACE, SUNRISE FL 33323
James S Turley director 9 MUIRFIELD LANE, SAINT LOUIS MO 63141
Ares Trading S.a. 10 percent owner ZONE INDUSTRIELLE DE L'OURIETTAZ, AUBONNE V8 1170

Precigen (Precigen) Headlines

From GuruFocus

Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T� with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023

By PRNewswire PRNewswire • 04-17-2023

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse� Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

By PRNewswire PRNewswire • 06-03-2023

Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics

By PRNewswire PRNewswire • 08-22-2022

Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025

By PRNewswire • 08-09-2023

Precigen Announces Closing of Public Offering of Common Stock

By PRNewswire PRNewswire • 01-27-2023

Precigen to Participate in Upcoming Leading Investor and Industry Conferences

By PRNewswire • 09-19-2023

Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

By PRNewswire PRNewswire • 01-12-2023

Director Jeffrey Kindler Sells 96,686 Shares of Precigen Inc

By GuruFocus Research • 12-31-2023

Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

By PRNewswire PRNewswire • 05-31-2023

Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

By PRNewswire • 08-09-2023